Neostem (NBS) 2.91 $NBS 3 Breakout Stocks Under $10 for

New Post Public Reply Private Reply Replies (0) Message Board

Apr 26, 2015 at 1:26 PM

Neostem (NBS) 2.91 $NBS

3 Breakout Stocks Under $10 for Your Trading Radar
at The Street - Thu Apr 23, 12:58PM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
MCEP: 6.38 (+0.12), NBS: 2.91 (-0.14), NSLP: 5.20 (-0.30)

NeoStem Announces Expanded Cell Therapy Manufacturing Relationship With Kite Pharma
GlobeNewswire - Mon Apr 20, 6:30AM CDT
NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell-based individualized medicine therapies, announced today the expansion of manufacturing services under an existing Services Agreement between its wholly-owned subsidiary, PCT, and Kite Pharma, Inc. (Nasdaq:KITE) (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer.
KITE: 60.58 (-0.35), NBS: 2.91 (-0.14)

Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Life Sciences Report - Seeking Alpha - Thu Apr 09, 4:59PM CDT
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised...
PSTI: 2.82 (-0.05), NBS: 2.91 (-0.14), OSIR: 16.33 (-0.26), BCLI: 4.14 (+0.02), MDVN: 131.01 (-1.50), INO: 10.35 (-0.25), CYTX: 0.99 (+0.01), STEM: 0.61 (-0.21), JUNO: 56.66 (-1.06), ATHX: 1.29 (-0.03), CUR: 1.94 (-0.06), BLUE: 136.26 (-3.82), VRTX: 133.20 (-2.62), AMGN: 167.91 (-1.26), KERX: 11.41 (-0.32), OMER: 24.32 (-0.35), KITE: 60.58 (-0.35), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), TEVA: 64.41 (+1.16)

NeoStem Announces Extension of Study Under Grant From California Institute of Regenerative Medicine (CIRM) to Fund Research of Retinal Disease
GlobeNewswire - Thu Apr 09, 6:30AM CDT
NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell based personalized medicine therapies, announced today the extension of its study under a 2014 Early Translational grant from the California Institute of Regenerative Medicine for research leading to the development of a treatment for retinal diseases, including macular degeneration and retinitis pigmentosa.
NBS: 2.91 (-0.14)

Cellular Biomedicine: Strong Sell On CAR-T Failure, Dishonesty Allegations And Stock Promotion, -94.6% Downside
The Pump Stopper - at Seeking Alpha - Tue Apr 07, 11:23AM CDT
I believe Cellular Biomedicine (NASDAQ: CBMG ) is another worthless Chinese reverse merger using paid stock promotion. Detailed research proves CBMG has imminent -87% to -94.6% near-term downside. CBMG was previously focusing on Nintendo screens...
NBS: 2.91 (-0.14), IBB: 363.70 (-3.98), OHRP: 2.94 (+0.12), CBMG: 29.51 (-1.85)

NeoStem to Present at Multiple April Conferences
GlobeNewswire - Mon Apr 06, 6:30AM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"

, a biopharmaceutical company developing novel cell-based personalized medicine therapies, announced today that the Company's management and experts will present at multiple conference in April.
NBS: 2.91 (-0.14)

Hot Stock: Neostem, Shares Gain 6.1% (NBS)
Comtex SmarTrend(R) - Thu Apr 02, 12:49PM CDT
Neostem (AMEX:NBS) is one of today's best performing low-priced stocks, up 6.1% to $2.78 on 1.2x average daily volume. Thus far today, Neostem has traded 449,000 shares, vs. average volume of 389,000 shares per day. The stock has outperformed the Dow (6.1% to the Dow's 0.3%) and outperformed the S&P 500 (6.1% to the S&P's 0.3%) during today's trading.
NBS: 2.91 (-0.14)

NeoStem (NBS) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 31, 7:09AM CDT
NeoStem (NBS) Enters Oversold Territory
NBS: 2.91 (-0.14)

Stock to Watch: Neostem Down 6.1% (NBS)
Comtex SmarTrend(R) - Mon Mar 30, 11:45AM CDT
Neostem (AMEX:NBS) is one of today's worst performing low-priced stocks, down 6.1% to $2.60 on 1.2x average daily volume. Thus far today, Neostem has traded 423,000 shares, vs. average volume of 356,000 shares per day. The stock has underperformed the Dow (-6.1% to the Dow's 1.6%) and underperformed the S&P 500 (-6.1% to the S&P's 1.1%) during today's trading.
NBS: 2.91 (-0.14)

Neostem Down 5.2%, Shares Slide into the Red (NBS)
Comtex SmarTrend(R) - Wed Mar 25, 11:46AM CDT
Neostem (AMEX:NBS) is one of today's worst performing low-priced stocks, down 5.2% to $3.11 on 1.0x average daily volume. Neostem has traded 314,000 shares thus far today, vs. average volume of 312,000 shares per day. The stock has underperformed the Dow (-5.2% to the Dow's -1.1%) and underperformed the S&P 500 (-5.2% to the S&P's -0.9%) during today's trading.
NBS: 2.91 (-0.14)

NeoStem, Inc. - "CEO Letter to Shareholders"
ACCESSWIRE - Thu Mar 19, 9:02AM CDT
NEW YORK, NY / ACCESSWIRE / March 19, 2015 / NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Chief Executive Officer , David Mazzo. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
NBS: 2.91 (-0.14)

NeoStem Announces PreSERVE AMI Clinical Trial One-Year Follow-Up Results
GlobeNewswire - Mon Mar 16, 5:00AM CDT
NeoStem, Inc. (Nasdaq:NBS), a biopharmaceutical company developing novel cell based personalized medicine therapies, announced today the presentation of updated efficacy and safety results from the one-year follow-up for its Phase 2 PreSERVE study and additional analyses of certain functional tests at ACC.15, the American College of Cardiology's 64th Annual Scientific Session and Expo, in San Diego, California. The one-year follow-up results are defined as all data accumulated until the last patient enrolled completed 12 month follow-up. Thus, the results actually represent data from patients with a median follow-up of 18 months.
NBS: 2.91 (-0.14)

NeoStem's One-Year Trial Results Could Bounce Shares
Austin Moss - at Seeking Alpha - Thu Mar 12, 1:27PM CDT

NBS: 2.91 (-0.14)

NeoStem to Present at Two Upcoming Investor Conferences in March
GlobeNewswire - Thu Mar 12, 6:30AM CDT
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"

, a biopharmaceutical company developing novel cell based personalized medicine therapies, announced today that the Company's management will present at the BioCentury Future Leaders in the Biotech Industry Conference on March 20 and at the Alliance for Regenerative Medicine Regen Med Investor Day on March 25.
NBS: 2.91 (-0.14)

Quarterly Report Card: Special Research on Magellan Health, Neostem, Ensign, USMD Holdings, and Adeptus Health
PR Newswire - Tue Mar 10, 7:00AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ENSG: 45.68 (+0.32), NBS: 2.91 (-0.14), USMD: 10.39 (+0.02), ADPT: 63.78 (+2.13), MGLN: 71.19 (-0.02)

NeoStem ups revenues 22% in FY14
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:38AM CST

NBS: 2.91 (-0.14)

NeoStem beats by $0.10, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 3:45PM CST

NBS: 2.91 (-0.14)

NeoStem, Inc. Announces 2014 Year-End Financial Results and Provides Corporate Update
GlobeNewswire - Mon Mar 02, 3:01PM CST
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"

, a biopharmaceutical company developing novel, cell-based personalized medicine therapies, announced today 2014 year end results and provided an update on its business.
NBS: 2.91 (-0.14)

NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST

CAPR: 7.25 (-0.75), OCAT: 7.48 (+0.02), VCEL: 3.52 (-0.06), PSTI: 2.82 (-0.05), NBS: 2.91 (-0.14), GSK: 46.59 (+0.28), IMUC: 0.53 (-0.01), KITE: 60.58 (-0.35), BAX: 71.14 (-0.37), ONCE: 61.39 (-0.66), JUNO: 56.66 (-1.06), ATHX: 1.29 (-0.03), CUR: 1.94 (-0.06)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

The Braff Group's 400th Health Care M&A Milestone

No one just stumbles into 400 successful deals without a whole lot of grit, especially in the gnarly jungle of health care services mergers and acquisitions. The Braff Group, a stalwart in this arena since 1998, has just hit this remarkable milestone. If you ask me, this isn't just a number—it's a testament to the blood, sweat, and relentless dedication poured into...

Guaranteed Income Policies Gain Traction Across States

Big Wins for Guaranteed Income Programs Boy, isn't it fascinating watching the political gears turn to embrace concepts like guaranteed income? This wave of enthusiasm isn't just words and ideas; it's now showing up in election results and ballot measures in multiple states. From California to Pennsylvania, voters appear to dig the idea of direct cash assistance to those...

Dircks Expands with Major Phoenix Lease Deal

Another Big Win in Phoenix's Industrial Space Who'd have thought? Dircks Moving & Logistics just bagged themselves a hefty 337,897-square-foot lease in Phoenix. This isn’t just any warehouse deal in the Southwest Valley—it’s a mark of where the industrial real estate world’s trending these days. For those who watch these things, they’ve pushed their local space...

CMS Fee Adjustments Aid Orthopaedics, But Issues Stay

A Partial Win for Orthopaedic Care Access This week, we’ve got a sigh of relief rolling through the orthopaedic corridors with the Centers for Medicare & Medicaid Services (CMS) dialing back on its proposed fee cuts. You’d think they were about to pull the rug out from beneath procedures most patients can't afford to get scarce. It’s not a full victory, but...

Veteran-Friendly U.S. Cities in 2026: Who's Leading?

Veterans Find Their Business Groove in U.S. Cities Around the diner's counter, traders might be swapping tales of market victories or lamenting lost opportunities. But today, we're chewing over a different kind of success story—the top U.S. cities paving the way for veteran entrepreneurs, courtesy of a fresh report from the PenFed Foundation for Military Heroes. This...

What's the Deal with Generations+ at P.C. Richard & Son? Felt like companies were giving away the farm just to keep customers hooked, and then I heard about P.C. Richard & Son's latest play. They've been around for a scorching 117 years, and now they're offering something they've never done before: a free membership program called Generations+ that tosses perks like candy...

Menarini & Ryvu's Phase II Results Offer Hope in B-NHL

New Glimmers of Hope in B-cell NHL Battle Battling aggressive B-cell non-Hodgkin lymphoma (B-NHL) isn't for the faint of heart, especially when standard treatments have been run through like an old pair of boots. Enter dapolsertib, the fresh-faced newcomer in Menarini Group and Ryvu Therapeutics' arsenal, showing encouraging signals in early Phase II results. These...

HSBC Unveils $1B Tender Offer to Manage Capital Base

HSBC's Strategic Capital Maneuver Alright, let's chew on this one: HSBC's out to repurchase up to a cool billion bucks worth of its own security paper. We're talking about the $3 billion, 6% Perpetual Subordinated Contingent Convertible Securities, which can be called up as soon as May 2027. Now, they're not going all-in—the offer is capped at $1 billion, though the...

Edelson Lechtzin Investigates Baanx Data Breach

Inside the Baanx Data Breach: A Wake-Up Call The digital currency frontier is fraught with pitfalls, and the latest Baanx data breach saga is a sobering reminder. This isn't just a minor fumble—this one's a big, hairy mess involving sensitive data of Crypto Life users, causing ripples through an already jittery market. What Went Wrong with Baanx We're staring at...

MY DR NOW Expands: Seven-Day Clinics Open Everywhere

Breaking The Mold Of Traditional Medicine MY DR NOW isn't here to play by the age-old rules. They're slinging open the doors to their newest family medicine clinics and kicking the old Monday-to-Friday scheduling straight to the curb. Every single day of the week, from 8 a.m. to 8 p.m., patients in Sunnyvale and Tucson are getting a dose of healthcare that's all about...